Esperion Therapeutics Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a note issued to investors on Saturday. They currently have a $30.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $64.00. Stifel Nicolaus’ price target suggests a potential upside of 148.96% from the company’s current price.

A number of other brokerages have also issued reports on ESPR. Credit Suisse Group AG lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $23.00 to $10.00 in a research note on Wednesday, June 29th. JPMorgan Chase & Co. lowered shares of Esperion Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $50.00 to $15.00 in a research note on Wednesday, June 29th. Royal Bank Of Canada lowered shares of Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $30.00 to $15.00 in a research note on Wednesday, June 29th. Lake Street Capital dropped their price target on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, June 29th. Finally, Citigroup Inc. reiterated a “buy” rating and set a $22.00 price target (down from $36.00) on shares of Esperion Therapeutics in a research note on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $26.08.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down 7.38% on Friday, reaching $12.05. 586,802 shares of the company were exchanged. The company’s market capitalization is $271.73 million. Esperion Therapeutics has a 52-week low of $9.58 and a 52-week high of $30.41. The stock has a 50 day moving average of $12.34 and a 200-day moving average of $13.96.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.16. During the same quarter last year, the business earned ($0.55) earnings per share. On average, analysts predict that Esperion Therapeutics will post ($3.37) EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its position in Esperion Therapeutics by 42.4% in the second quarter. JPMorgan Chase & Co. now owns 142,161 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 42,361 shares in the last quarter. Swiss National Bank raised its position in Esperion Therapeutics by 7.2% in the second quarter. Swiss National Bank now owns 22,200 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 1,500 shares in the last quarter. Quantitative Investment Management LLC purchased a new position in Esperion Therapeutics during the second quarter worth $111,000. California State Teachers Retirement System raised its position in Esperion Therapeutics by 8.1% in the second quarter. California State Teachers Retirement System now owns 30,016 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 2,251 shares in the last quarter. Finally, FNY Managed Accounts LLC purchased a new position in Esperion Therapeutics during the second quarter worth $1,976,000. 65.22% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.